Pharvaris' Deucrictibant Presents Opportunity in Hereditary Angioedema Market, RBC Says

MT Newswires Live

Mar 09

Pharvaris (PHVS) could gain a position in the hereditary angioedema treatment market with its oral drug candidate deucrictibant, supported by clinical data and upcoming milestones, RBC Capital Markets said in a note Monday.

The firm said data from a phase 3 study of deucrictibant's immediate-release formulation presents it "as potentially the most effective oral drug in the on-demand treatment of hereditary angioedema attacks."

RBC expects the company to submit a new drug application for the immediate-release formulation in H1, with a potential launch in 2027.

The firm also said the drug's extended-release version, which is being evaluated for preventive treatment of HAE in a phase 3 trial, could disrupt the prophylaxis market.

RBC said the combination of potential on-demand and preventive uses for deucrictibant could lead to Pharvaris capturing market share if development programs are successful.

RBC initiated coverage of Pharvaris with an outperform rating and a $52 price target.

Price: 26.21, Change: +0.30, Percent Change: +1.16

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2618627272"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618627272\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618627272?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618627272","market":"nz","top_or_hot":-1,"title":"Pharvaris' Deucrictibant Presents Opportunity in Hereditary Angioedema Market, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Pharvaris (PHVS) could gain a position in the hereditary angioedema treatment market with its oral drug candidate deucrictibant, supported by clinical data and upcoming milestones, RBC Capital Markets said in a note Monday.</p><p>The firm said data from a phase 3 study of deucrictibant's immediate-release formulation presents it \"as potentially the most effective oral drug in the on-demand treatment of hereditary angioedema attacks.\"</p><p>RBC expects the company to submit a new drug application for the immediate-release formulation in H1, with a potential launch in 2027.</p><p>The firm also said the drug's extended-release version, which is being evaluated for preventive treatment of HAE in a phase 3 trial, could disrupt the prophylaxis market.</p><p>RBC said the combination of potential on-demand and preventive uses for deucrictibant could lead to Pharvaris capturing market share if development programs are successful.</p><p>RBC initiated coverage of Pharvaris with an outperform rating and a $52 price target.</p><p>Price: 26.21, Change: +0.30, Percent Change: +1.16</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris' Deucrictibant Presents Opportunity in Hereditary Angioedema Market, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris' Deucrictibant Presents Opportunity in Hereditary Angioedema Market, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-09 23:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pharvaris (PHVS) could gain a position in the hereditary angioedema treatment market with its oral drug candidate deucrictibant, supported by clinical data and upcoming milestones, RBC Capital Markets said in a note Monday.</p><p>The firm said data from a phase 3 study of deucrictibant's immediate-release formulation presents it \"as potentially the most effective oral drug in the on-demand treatment of hereditary angioedema attacks.\"</p><p>RBC expects the company to submit a new drug application for the immediate-release formulation in H1, with a potential launch in 2027.</p><p>The firm also said the drug's extended-release version, which is being evaluated for preventive treatment of HAE in a phase 3 trial, could disrupt the prophylaxis market.</p><p>RBC said the combination of potential on-demand and preventive uses for deucrictibant could lead to Pharvaris capturing market share if development programs are successful.</p><p>RBC initiated coverage of Pharvaris with an outperform rating and a $52 price target.</p><p>Price: 26.21, Change: +0.30, Percent Change: +1.16</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618627272","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618627272","pubTimestamp":1773068816,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pharvaris  could gain a position in the hereditary angioedema treatment market with its oral drug candidate deucrictibant, supported by clinical data and upcoming milestones, RBC Capital Markets said in a note Monday.The firm said data from a phase 3 study of deucrictibant's immediate-release formulation presents it \"as potentially the most effective oral drug in the on-demand treatment of hereditary angioedema attacks.\"RBC expects the company to submit a new drug application for the immediate-release formulation in H1, with a potential launch in 2027.The firm also said the drug's extended-release version, which is being evaluated for preventive treatment of HAE in a phase 3 trial, could disrupt the prophylaxis market.RBC said the combination of potential on-demand and preventive uses for deucrictibant could lead to Pharvaris capturing market share if development programs are successful.RBC initiated coverage of Pharvaris with an outperform rating and a $52 price target.Price: 26.21, C","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PHVS":"Pharvaris N.V."},"translate_title":"加拿大皇家银行表示，Pharvaris的Deucrictibant为遗传性血管性水肿市场带来了机遇","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHVS":1},"content_text":"Pharvaris (PHVS) could gain a position in the hereditary angioedema treatment market with its oral drug candidate deucrictibant, supported by clinical data and upcoming milestones, RBC Capital Markets said in a note Monday.The firm said data from a phase 3 study of deucrictibant's immediate-release formulation presents it \"as potentially the most effective oral drug in the on-demand treatment of hereditary angioedema attacks.\"RBC expects the company to submit a new drug application for the immediate-release formulation in H1, with a potential launch in 2027.The firm also said the drug's extended-release version, which is being evaluated for preventive treatment of HAE in a phase 3 trial, could disrupt the prophylaxis market.RBC said the combination of potential on-demand and preventive uses for deucrictibant could lead to Pharvaris capturing market share if development programs are successful.RBC initiated coverage of Pharvaris with an outperform rating and a $52 price target.Price: 26.21, Change: +0.30, Percent Change: +1.16","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}